Stage-specific quality of life and tolerability of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer: a narrative review. (PubMed, Oncology) - Oct 8, 2026 - "Global HRQoL, individual symptoms, and continuation answer different questions. Discussions about metastatic treatment should integrate disease control and sequencing; discussions about adjuvant treatment should address absolute recurrence reduction and planned duration. Both require consideration of baseline symptoms, uncertainty, and individual priorities."
HEOR • Journal • Review • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2
|
|
Anna Rita Amato; Carlo Buonerba; Germano Guerra; Giuseppe Di Lorenzo; Luca Scafuri; Vincenzo Marotta
|